Criteria of Progression for Trial Eligibility By Disease Manifestation | Download Table
Prostate Cancer Working Group Updates CRPC Clinical Trial Guidelines - Cancer Therapy Advisor
Advanced Prostate Cancer: Treatment Advances and Future Directions: Trends in Cancer
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer | NEJM
The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors | Prostate Cancer and Prostatic Diseases
Table 1 from Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. | Semantic Scholar
Prostate Cancer Working Group 3 (PCWG3) Criteria in Clinical Trials | PCCTC
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration | Journal of Clinical Oncology
Table of Contents page: Clinical Genitourinary Cancer
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 | Journal of Clinical Oncology
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 | Journal of Clinical Oncology
Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511
![PDF] Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/46d1d0ae52e9c099508514ee695d109b6334231c/2-Figure1-1.png "PDF] Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. | Semantic Scholar")
PDF] Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. | Semantic Scholar
Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium - Clinical Genitourinary Cancer
Second-line Hormonal Therapy for the Management of Metastatic Castration-resistant Prostate Cancer: a Real-World Data Study Using a Claims Database | Scientific Reports
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial - The Lancet Oncology
Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer - European Urology Focus
Managing Castrate- Resistant Metastatic Prostate Cancer Elisabeth I. Heath, MD Associate Professor of Medicine and Oncology Wayne State University/Karmanos. - ppt download
Implementing Prostate Cancer Working Group 3 Criteria in Clinical Trials- Michael Morris and Lawrence Schwartz
Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art | Radiology
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent - European Urology
![PDF] Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/46d1d0ae52e9c099508514ee695d109b6334231c/4-Table2-1.png "PDF] Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. | Semantic Scholar")
PDF] Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. | Semantic Scholar
Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis - The Lancet Oncology
AUA 2020: Apalutamide for Metastatic Castration-Sensitive Prostate Cancer in TITAN: Prognostic Importance of Prostate-Specific Antigen Responses
Figure 1 from Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. | Semantic Scholar
ESMO 2021: Apalutamide Efficacy and Safety in Asian Patients with Metastatic Castration-Sensitive Prostate Cancer
